Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY-Enhanced 2D-Echo and Magnetic Resonance Imaging

Trial Profile

A Phase III, Open-Label, Multicenter Trial to Evaluate Ejection Fraction, End-Diastolic and End-Systolic Volumes, by Unenhanced and DEFINITY-Enhanced 2D-Echo and Magnetic Resonance Imaging

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2019

At a glance

  • Drugs Perflutren (Primary)
  • Indications Cardiovascular disorders
  • Focus Diagnostic use; Registrational
  • Acronyms BENEFIT1
  • Sponsors Lantheus Medical Imaging
  • Most Recent Events

    • 24 Oct 2018 Status changed from not yet recruiting to recruiting.
    • 01 Oct 2018 Planned initiation date changed from 1 Sep 2018 to 1 Oct 2018.
    • 04 Jul 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top